Related Experiment Video
Updated: Jul 5, 2025
09:09
Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
Published on: June 23, 2020
6.0K
Anti-CD64 Antibody-Conjugated PLGA Nanoparticles Containing Methotrexate and Gold for Theranostics Application in
1Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, SVKM'S NMIMS, V. L. Mehta Road, Vile Parle (W), Mumbai, India.
AAPS Pharmscitech
|January 24, 2024
Summary
Researchers developed novel PLGA nanoparticles for rheumatoid arthritis treatment. These antibody-conjugated nanoparticles effectively delivered methotrexate, improving clinical outcomes and reducing side effects in animal models.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Immunology
Background:
- Rheumatoid arthritis (RA) is an autoimmune disease significantly impacting patient quality of life.
- Current understanding of RA's inflammatory mechanisms is incomplete, necessitating new therapeutic and diagnostic approaches.
- Developing effective drug delivery systems is crucial for managing RA and minimizing treatment-related toxicity.
Purpose of the Study:
- To engineer a novel drug delivery system for rheumatoid arthritis (RA).
- To encapsulate gold and methotrexate within PLGA nanoparticles.
- To conjugate anti-CD64 antibodies to the nanoparticle surface for targeted delivery.
Main Methods:
- Poly(lactic-co-glycolic acid) (PLGA) nanoparticles were synthesized.
- Gold and methotrexate were incorporated into the nanoparticle core.
- Anti-CD64 antibodies were conjugated to the nanoparticle surface.
- Nanoparticle characterization included SEM, TEM, particle size, zeta potential, and PDI analysis.
- In vitro drug release studies were conducted under varying pH conditions.
- In vivo efficacy was evaluated in an adjuvant-induced arthritis rat model.
Main Results:
- Nanoparticles exhibited good stability and homogeneity (size: 413.6 ± 2.89 nm, PDI: 0.23 ± 0.04).
- Controlled drug release was observed, with 93.44% release within 72 hours at pH 5.8, influenced by pH and NIR.
- Antibody-conjugated nanoparticles significantly improved clinical indices and arthritic scores in rats compared to non-conjugated nanoparticles and free drugs.
Conclusions:
- The developed anti-CD64 antibody-conjugated PLGA nanoparticles represent an innovative strategy for rheumatoid arthritis therapy.
- This targeted drug delivery system enhances therapeutic efficacy by concentrating medication at the disease site.
- The system holds potential for maximizing treatment effectiveness while minimizing dosage-related side effects in RA patients.
